ProPhase Labs Inc. addressed recent volatility in its stock price, attributing it to technical factors such as accelerated convertible debt conversions, a 1-for-10 reverse stock split, and the company’s move from Nasdaq to the OTC market. Management emphasized that these changes, while affecting share count and price, do not alter the intrinsic value of the company’s assets. The recent debt conversions have reduced liabilities and strengthened the balance sheet. ProPhase Labs highlighted the continued value of its core assets, including the Crown Medical receivables recovery initiative, the BE-Smart Esophageal Cancer diagnostic test, and Nebula Genomics/DNA Complete, and reassured shareholders that recent market activity does not reflect changes in the company’s long-term prospects.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ProPhase Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9619542-en) on January 05, 2026, and is solely responsible for the information contained therein.